Younger, Non-White Women With Sarcoidosis Have Pulmonary Hypertension

Younger, non-White patients with sarcoidosis who are women are at increased risk for pulmonary hypertension.

Among patients with sarcoidosis, non-White patients who are younger and women are at increased risk for pulmonary hypertension (PH), according to results of a study presented at the American Heart Association (AHA) Scientific Sessions 2022, held from November 5th through 7th, in Chicago, Illinois.

A risk factor of advanced sarcoidosis is PH, which in turn is associated with increased risk for mortality.

Investigators from the University of Florida conducted a nationwide, retrospective study to evaluate diagnostic and management strategies for PH in the setting of sarcoidosis. Data were sourced from a national registry associated with FSR-SARC (the Foundation for Sarcoidosis Research). Participants responded to surveys about demographics, symptoms of sarcoidosis, PH status, and sarcoidosis treatments between 2014 and 2019.

Among the 3835 FSR-SARC participants, 211 (6%) had PH.

The PH cohort had a mean age of 42 (SD, 13) years, 66% were women, 60% were White, and 33% were Black. The patients with PH were younger (mean, 42 vs 44 years; P =.008), more were women (odds ratio [OR], 1.5; 95% CI, 1.1-2.0; P =.006), and fewer were White (P <.0001) compared with the patients who did not report PH.

The PH cohort reported receiving steroid (79%), cytotoxic (46%), and/or tumor necrosis factor (TNF) inhibitor (19%) therapies. Having PH increased the likelihood of receiving TNF inhibitors (OR, 1.7; 95% CI, 1.2-2.4; P =.004) and cytotoxic medications (OR, 1.5; 95% CI, 1.1-1.9; P =.008) compared with not having PH.

The major limitations of this study are the small sample size and the reliance on self-reported data.

These data indicated that, among patients with sarcoidosis, those who were younger, non-White, and/or women were at greater risk for developing PH. The presence of PH increased the likelihood of receiving more aggressive sarcoidosis treatments, including TNF inhibitors and cytotoxic medications.


Sayaideh MA, Younis M, Alzghoul B. Diagnostic and therapeutic practices of pulmonary arterial hypertension in patients with sarcoidosis in the United States: a nationwide registry study. Presented at: The American Heart Association (AHA) Scientific Sessions 2022; November 5-7, 2022; Chicago, IL. Abstract #MO416.